Navigation Links
Flagship Biosciences Launches New Clinical Diagnostics Service
Date:7/1/2020

Flagship Biosciences, providers of expert tissue data insights, today announced that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight. TissueInsight provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment (TME).

“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” said Trevor Johnson, Flagship CEO. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”

Flagship’s exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab delivers the highly accurate tissue scoring needed for precision medicine. Combined with its award-winning technology and sign-off from its experienced pathologists for every client, TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring. Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages.

“I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson. “Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immuno-oncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.”

About Flagship Biosciences

Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation for every client, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. flagshipbio.com

For more information please contact Pamela Curran of Stratos Global Marketing, at pam@stratosglobalmarketing.com or +1 (303) 818 9316.

Read the full story at https://www.prweb.com/releases/flagship_biosciences_launches_new_clinical_diagnostics_service/prweb17223687.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Predicine and Flagship Biosciences Partner to Support Global Biomarker Development
2. Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
3. Orthogonal Congratulates Nanowear on the FDA Clearance of their Flagship Product, SimplECG™.
4. Dr. Nancy Gillett Joins Flagship Biosciences' Board of Directors
5. Flagship Biosciences Expands Operations to Meet Tremendous Industry Growth Demands
6. Flagship Biosciences and Beaufort, LLC Partner to Provide Clinical Trial Services for the Pharmaceutical Industry
7. Flagship Ventures Brian Fiske Named To Forbes 30 Under 30 List
8. Flagship Creates Clinical Trials and Regulatory Affairs Group
9. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. Deep Knowledge Ventures Flagship Investment Insilico Medicine Finalist at GPU Tech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... Editas ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... entered into a strategic partnership whereby Catalent will provide support for the development, ...
(Date:7/18/2020)... ... 16, 2020 , ... After research model surgery and catheter implantation, the long ... only the beginning of a successful study, while protecting and accessing the catheter or ... Head of Surgery from Envigo in a live webinar on ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... today that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive ... PathSensors to move into the point-of-care diagnostic market, focusing initially on the ...
(Date:7/1/2020)... (PRWEB) , ... June 29, 2020 , ... ... year to date growth of 40% in 2020, despite many obstacles created as ... MedShift aims to increase revenue for its partnered medical practices and medical manufacturers ...
Breaking Biology Technology:
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in a ... the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles ... on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader in ... Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , ... Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):